Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
144.00    -1.00 (-0.69%)
Bid:
144.00
Ask:
145.00
Spread: 1.00 (0.694%)
Market Cap: £113.00m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Trading Statement

19 Jan 2012 07:00

RNS Number : 8017V
Xaar PLC
19 January 2012
 



 

 

 

FOR IMMEDIATE RELEASE

19 January 2012

 

 

 

Xaar plc

 

 

YEAR END TRADING UPDATE

 

 

Xaar plc ("Xaar" or "the Group" or "the Company"), the inkjet printing technology group headquartered in Cambridge, announces an update on trading for the year ended 31 December 2011.

 

Trading for the fourth quarter of the year was slightly ahead of the Board's expectations, leading to a strong performance for the full year 2011.

 

Xaar expects to announce revenue of approximately £69 million for 2011, an increase of over 25% compared to 2010 (£54.7 million).

 

Revenue growth in 2011 was achieved mainly by increased sales into the industrial segment. Demand for Xaar's technology in this segment is principally driven by the conversion of ceramic tile printing to digital inkjet from analogue processes. During the year, Xaar made good progress with the capacity expansion programme to support this demand and the programme remains on track to continue to deliver the planned incremental capacity during the first half of 2012.

 

As expected, product sales into the graphic arts segment declined in 2011 by approximately 15% compared to 2010. As previously described, this decline reflects market maturity and competitive pressure.

 

The Group continues to maintain a strong balance sheet with net cash at 31 December 2011 of £17.4 million (30 June 2011 - £20.6 million; 31 December 2010 - £22.0 million).

 

The detailed results for 2011 are expected to be announced on 20 March 2012.

 

Board changes

 

As previously announced Phil Eaves, Sales and Marketing Director, informed the Company in 2011 of his intention to retire from full time employment in June 2012. Following an extensive search process, the Company is pleased to announce that Richard Barham has been appointed Sales and Marketing Director and member of the Xaar board with effect from 5 March 2012. After completion of a handover period, Phil Eaves will continue to support the Company in a consultant role until 30 June 2012.

 

Ian Dinwoodie, Chief Executive commented:

 

'On behalf of everyone at Xaar, I would like to thank Phil for his efforts and contribution over the last 7 years during which our revenues have grown significantly. We all wish him well for the future.

 

I am pleased to welcome Richard to the Board, who brings a wealth of experience gained through 25 years spent in numerous sectors of the Imaging and Printing industries.'

Since 1986, Mr Barham has held a range of sales, marketing and management positions at Agfa Graphics NV, where most recently, since February 2008, he acted as Vice President of the Inkjet Division where he was responsible for turning the business around and integrating a major acquisition.

 

There is no further information concerning Mr Barham which requires disclosure under rule 9.6.13 of the UK Listing Authority Listing Rules.

 

 

END

 

CONTACTS

 

Xaar plc:

01223-423663

Ian Dinwoodie, Chief Executive

www.xaar.com

Alex Bevis, Finance Director

Singer Capital Markets Limited:

020-3205-7500

Shaun Dobson

Bankside Consultants:

Simon Bloomfield

020-7367-8888 / 07771-758517

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDVLFFLFFFBBB
Date   Source Headline
3rd Feb 20254:15 pmRNSTotal Voting Rights
22nd Jan 202512:30 pmRNSBlock listing Interim Review
21st Jan 20253:00 pmRNSHolding(s) in Company
15th Jan 20257:00 amRNSTrading update & notification of full year results
15th Jan 20257:00 amRNSAppointment of Chief Financial Officer
11th Dec 202410:30 amRNS2024 Full Year Trading Update
4th Dec 202410:45 amRNSUpdate statement on 2024 AGM voting results
3rd Dec 202410:50 amRNSTotal Voting Rights
20th Nov 20247:00 amRNSBoard changes
1st Nov 202412:00 pmRNSTotal Voting Rights
1st Oct 202411:30 amRNSTotal Voting Rights
18th Sep 20247:00 amRNSInterim Results
2nd Sep 20241:45 pmRNSTotal Voting Rights
2nd Aug 20242:30 pmRNSHolding(s) in Company
1st Aug 202411:15 amRNSTotal Voting Rights
30th Jul 20247:00 amRNSNOTICE OF RESULTS AND UPDATE ON TRADING
3rd Jul 202411:45 amRNSBlock listing Interim Review
2nd Jul 20242:00 pmRNSTotal Voting Rights
28th Jun 202410:00 amRNSDirector Declaration
3rd Jun 20242:45 pmRNSTotal Voting Rights
30th May 202412:00 pmRNSBoard changes
29th May 20241:45 pmRNSResult of AGM
29th May 20249:30 amRNSHolding(s) in Company
21st May 20249:30 amRNSDirector/PDMR Shareholding
20th May 20244:30 pmRNSDirector/PDMR Shareholding
13th May 20249:42 amRNSHolding(s) in Company
1st May 20244:15 pmRNSTotal Voting Rights
30th Apr 20244:30 pmRNSDirector/PDMR Shareholding
22nd Apr 202410:51 amRNSAnnual Financial Report
2nd Apr 202412:00 pmRNSTotal Voting Rights
1st Mar 202410:15 amRNSTotal Voting Rights
26th Feb 20249:00 amRNSHolding(s) in Company
23rd Feb 202410:30 amRNSBoard Change
1st Feb 20241:32 pmRNSTotal Voting Rights
29th Jan 202412:04 pmRNSHolding(s) in Company
12th Jan 20243:15 pmRNSBlock listing Interim Review
12th Jan 20247:00 amRNSNotification of Results & Full year Guidance
8th Jan 202412:36 pmRNSTotal Voting Rights
12th Dec 20239:00 amRNSNotification of Transactions of Directors & PDMRs
11th Dec 20233:00 pmRNSNotification of Transactions of Directors & PDMRs
1st Dec 202311:00 amRNSTotal Voting Rights
1st Dec 202310:00 amRNSDirector Declaration
29th Nov 20237:00 amRNSTrading Update
17th Nov 20234:07 pmRNSHolding(s) in Company
9th Nov 20231:53 pmRNSDirector/PDMR Shareholding
3rd Nov 202310:52 amRNSHolding(s) in Company
1st Nov 20234:03 pmRNSTotal Voting Rights
30th Oct 20237:00 amRNSBoard Changes
2nd Oct 202311:45 amRNSTotal Voting Rights
21st Sep 20233:16 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.